Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Sillajen, Inc.

Clinical trials sponsored by Sillajen, Inc., explained in plain language.

SillaJen, Inc. 215600 KOSDAQ

A biopharmaceutical company developing oncolytic virus immunotherapies for cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Completed 2

New drug BAL0891 enters human trials for Tough-to-Treat cancers

Disease control Recruiting now

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC